MNG1137
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.363
- KRAS_SIGNALING_DN+0.352
- SPERMATOGENESIS+0.305
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.241
- COAGULATION+0.224
- ALLOGRAFT_REJECTION+0.178
- APICAL_SURFACE+0.081
- MYOGENESIS+0.079
- INFLAMMATORY_RESPONSE+0.033
- IL6_JAK_STAT3_SIGNALING+0.026
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.535
- PROTEIN_SECRETION-0.532
- MYC_TARGETS_V1-0.506
- UNFOLDED_PROTEIN_RESPONSE-0.482
- DNA_REPAIR-0.460
- ADIPOGENESIS-0.439
- MTORC1_SIGNALING-0.425
- TGF_BETA_SIGNALING-0.400
- ANDROGEN_RESPONSE-0.394
- PEROXISOME-0.377
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR662342 | GTEX | — | 0.942 |
| 2 | MDT-AP-1143 | Med | Medulloblastoma | 0.939 |
| 3 | MNG1003 | — | — | 0.934 |
| 4 | MNG1118 | — | — | 0.933 |
| 5 | MNG436 | — | — | 0.930 |
| 6 | MNG923 | — | — | 0.929 |
| 7 | SRR1337431 | GTEX | — | 0.929 |
| 8 | MNG1159 | — | — | 0.927 |
| 9 | SRR1348861 | GTEX | — | 0.927 |
| 10 | SRR1413454 | GTEX | — | 0.923 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.363 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.352 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.305 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.241 | Inavolisib | — uncovered |
| COAGULATION | 0.224 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.178 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.081 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.079 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.033 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.026 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.017 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.005 | Remibrutinib | — uncovered |